| CEO Name | Blaise Coleman |
| Nationality | United States |
| Net Worth Estimation | $10 million |
Blaise Coleman's estimated net worth of around $10 million is primarily derived from his executive compensation, stock awards, and bonuses as CEO of Endo International plc. His financial gains are closely tied to company performance, stock price fluctuations, and long-term incentive plans typical for pharmaceutical industry executives.
Blaise Coleman, CEO of Endo International plc, has an estimated net worth of $10,000,000, positioning him at the minimum range for pharmaceutical CEOs. This amount represents just 2% of the sector's maximum estimated CEO net worth of $500,000,000.
Business Category: Pharmaceutical
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 500000000 USD
Blaise Coleman Performance in Endo International plc
Blaise Coleman, CEO of Endo International plc, leverages strategic leadership and data-driven decision-making to stabilize the company's pharmaceutical portfolio and drive innovation. Under his guidance, Endo has improved operational efficiency and enhanced product development, positively impacting financial performance and market competitiveness. His leadership has been pivotal in navigating regulatory challenges and repositioning the company for sustainable growth.
Latest News
Mallinckrodt and Endo Complete Merger to Form Diversified Therapeutics Leader
Mallinckrodt plc and Endo, Inc. finalized their merger on August 1, 2025, creating a globally scaled therapeutics company with complementary branded, generics, and sterile injectables businesses. Siggi Olafsson serves as President and CEO, emphasizing growth, innovation, and shareholder value in the combined company, which plans NYSE listing post spin-off of some divisions in late 2025[11].
Source: http://www.prnewswire.com/news-releases/mallinckrodt-endo-complete-merger-to-create-global-scaled-diversified-therapeutics-leader-302519388.html